Sign in
CompletedPhase 2

Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Abreva in the Suppression of Herpes Simplex Virus Eruptions

Key facts

Who runs it
University of Utah
Where
Murray, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
58 people enrolled
Started
19 Aug 2024
Ended
30 Nov 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • acyclovir-penciclovir cream
  • Abreva
Record updated
27 October 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Understands the requirements of the study and provides written informed consent prior to undergoing any study-related procedures
  • Subject is a male or female between the ages of 18-80 years old, inclusive
  • Fitzpatrick skin type II or III
  • History of at least one year of herpes labialis induced by UV exposure
  • Able to recall exact location of most common or most recent outbreak
  • History of at least 50% of cold sore outbreaks occurring with UV (sun) exposure
  • At least 1 HSV-1 outbreak within the past 12 months
  • Experiences prodromal symptoms before HSV-1 outbreaks
  • Subject is willing and able to comply with protocol-specified dosing, visits to the clinic and tracking of pain

Who cannot take part

  • Outbreak <2 weeks prior to enrollment
  • On any systemic or topical steroid, immune suppressant or chemotherapeutic agent within the past 14 days
  • Use of tanning beds, history of sunburn, or beach vacation <2 weeks prior to enrollment
  • Current immunosuppressed state due to underlying disease (i.e. HIV infection) concomitant treatment (i.e. chemotherapy)
  • Alcohol or drug abuse
  • History of herpes simplex vaccine
  • History of photosensitivity, lupus erythematosus, or current use of a highly photosensitizing medication in the opinion of the investigator
  • Current upper respiratory tract infection or any active illness that could trigger cold sores or affect overall health of the patient or the assessment of the study agent
  • Abnormal skin conditions in the area of the recurrent HSV1 outbreaks
  • On antiviral suppression within the past 30 days
  • Requires more than acetaminophen for pain from recurrent HSV outbreaks
  • Pregnant or intending to become pregnant during the study
  • Enrolled in another clinical trial within the past 30 days
  • On any analgesics or NSAIDs that cannot be stopped during the study

Where in United States

  • University of Utah Midvalley DermatologyMurray, United States

About the trial

What the trial wants to find out

This will be a randomized, efficacy assessor-blinded, parallel group, pilot study of up to 40 subjects with documented herpes labialis. Patients will be treated with the study drug, acyclovir-penciclovir cream, or the active comparator of Abreva.

Read full original descriptionShow less

Potential subjects will be assessed during a screening visit that must take place no greater than 2 weeks prior to the Day 1 (Baseline) visit. During the screening period, subjects that meet all other entry criteria will undergo Ultraviolet susceptibility testing to determine the subject's individual minimal erythema dose (MED). Ultraviolet susceptibility testing takes place over two days with exposure to Ultraviolet light on specified regions on the subject's back followed by an assessment of the exposed areas 24 hours later to identify the MED. Subjects who have a measurable MED will be allowed to enroll in the study. Each subject will be randomly assigned in a 1:1 ratio to receive either acyclovir-penciclovir cream or Comparator (Abreva).

Patients who express a cold sore will track the lesion with a diary card to rate their pain levels, and any unusual symptoms at Day 1, Day 3, Day 5, Day 7, and Day 10. Patients may also take photographs of the lesion throughout the study.

The 2 groups in the trial

  • Study Drug (acyclovir-penciclovir cream)Treatment being tested

    Patients will treat herpes simplex eruption with active study drug.

    Treatment: acyclovir-penciclovir cream

  • Active Comparator (Abreva)Existing treatment, for comparison

    Patients will treat herpes simplex eruption with Abreva.

    Treatment: Abreva

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Parallel Group, Pilot Study to Assess Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Active Comparator (Abreva) in the Suppression of Herpes Simplex Virus Eruptions in Subjects With a History of Herpes Labialis
Record updated
27 October 2026